Fingerprint
Dive into the research topics of 'Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andrea Varga*, Sarina Piha-Paul, Patrick A. Ott, Janice M. Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
172
Scopus
citations